Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

AVIR

Atea Pharmaceuticals (AVIR)

Atea Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AVIR
DateHeureSourceTitreSymboleSociété
29/05/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
22/05/202413h00GlobeNewswire Inc.Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202422h43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
07/05/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
29/04/202413h00GlobeNewswire Inc.Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
27/03/202412h00GlobeNewswire Inc.Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsNASDAQ:AVIRAtea Pharmaceuticals Inc
28/02/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
21/02/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
03/02/202403h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
01/02/202422h15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
08/01/202422h05GlobeNewswire Inc.Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19NASDAQ:AVIRAtea Pharmaceuticals Inc
03/01/202413h00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
13/11/202313h00GlobeNewswire Inc.Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202322h05GlobeNewswire Inc.Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202313h00GlobeNewswire Inc.Atea Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:AVIRAtea Pharmaceuticals Inc
02/11/202312h00GlobeNewswire Inc.Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
01/11/202312h00GlobeNewswire Inc.Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
06/09/202313h00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
08/08/202322h05GlobeNewswire Inc.Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
01/08/202313h00GlobeNewswire Inc.Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
21/06/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVIRAtea Pharmaceuticals Inc
15/06/202313h00GlobeNewswire Inc.Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir CombinationNASDAQ:AVIRAtea Pharmaceuticals Inc
12/06/202314h20Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVIRAtea Pharmaceuticals Inc
30/05/202313h00GlobeNewswire Inc.Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesNASDAQ:AVIRAtea Pharmaceuticals Inc
23/05/202322h05GlobeNewswire Inc.Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesNASDAQ:AVIRAtea Pharmaceuticals Inc
08/05/202322h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVIRAtea Pharmaceuticals Inc
08/05/202322h05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
01/05/202322h05GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AVIR

Dernières Valeurs Consultées